JNJ-67856633 — Investigational Agent
Other · Phase 1 · Janssen (Johnson & Johnson)
Mechanism of Action
Oral allosteric inhibitor of MALT1 paracaspase, blocking the protease activity downstream of the CARD11-BCL10-MALT1 complex to shut off chronic BCR-driven NF-kB signaling in B-cell malignancies.
Investigational Indications
- Relapsed/refractory non-Hodgkin lymphoma
- Chronic lymphocytic leukemia